The Health Resources and Services Administration has “invoked the nuclear option of removal from not only the 340B program but also Medicaid and Medicare Part B if manufacturers implement a cash replenishment model, counsel for Eli Lilly—the manufacturer of Mounjaro, Trulicity and other treatments for weight loss or diabetes—alleged in their complaint.
The Health Resources and Services Administration has “invoked the nuclear option of removal from not only the 340B program but also Medicaid and Medicare Part B if manufacturers implement a cash replenishment model, counsel for Eli Lilly—the manufacturer of Mounjaro, Trulicity and other treatments for weight loss or diabetes—alleged in their complaint.
